Setanaxib

Global PBC Therapeutics Market Expected to Reach $1.4 Billion by 2032, Driven by Rising Incidence of PBC - ResearchAndMarkets.com

Retrieved on: 
Monday, October 16, 2023

The global Primary Biliary Cholangitis (PBC) Therapeutics market, valued at $683.95 million in 2022, is projected to grow significantly, reaching an estimated $1.4 billion by 2032, with a CAGR of 7.1% from 2023 to 2032.

Key Points: 
  • The global Primary Biliary Cholangitis (PBC) Therapeutics market, valued at $683.95 million in 2022, is projected to grow significantly, reaching an estimated $1.4 billion by 2032, with a CAGR of 7.1% from 2023 to 2032.
  • PBC Therapeutics refer to treatment options for managing and treating primary biliary cholangitis, a chronic autoimmune liver disease that primarily affects the small bile ducts within the liver.
  • Rising PBC Cases: The market's growth is driven by a surge in cases of primary biliary cholangitis and increasing awareness of the disease.
  • Advancements in Therapeutics: The continuous development and research of PBC therapeutics worldwide are propelling market growth.

Global Renal Fibrosis Clinical Trial Pipeline Report 2021: Clinical Trial Stages, Drug Mechanism Classes, Company, Short-term Launch Highlights - ResearchAndMarkets.com

Retrieved on: 
Monday, January 25, 2021

The "Global Renal Fibrosis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Renal Fibrosis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Renal Fibrosis Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Renal Fibrosis market.
  • It covers emerging therapies for Renal Fibrosis in active clinical development stages including early and late stage clinical trials.
  • The report provides Renal Fibrosis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Global Liver Fibrosis Clinical Trial Pipeline Report 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 20, 2021

The "Global Liver Fibrosis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Liver Fibrosis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Liver Fibrosis Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Liver Fibrosis market.
  • It covers emerging therapies for Liver Fibrosis in active clinical development stages including early and late stage clinical trials.
  • The report provides Liver Fibrosis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Global Diabetic Nephropathy Clinical Trial Pipeline Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 20, 2021

The "Global Diabetic Nephropathy Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Diabetic Nephropathy Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Diabetic Nephropathy Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Diabetic Nephropathy market.
  • It covers emerging therapies for Diabetic Nephropathy in active clinical development stages including early and late stage clinical trials.
  • The report provides Diabetic Nephropathy pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Positive Phase 1 results in high-dose setanaxib trial

Retrieved on: 
Monday, January 18, 2021

The Phase 1 study demonstrated that setanaxib is well tolerated at the doses tested, with no safety signal or dose-limiting toxicity being identified.

Key Points: 
  • The Phase 1 study demonstrated that setanaxib is well tolerated at the doses tested, with no safety signal or dose-limiting toxicity being identified.
  • The results provide an opportunity for the company to pursue a pivotal Phase 2/3 clinical trial in patients with primary biliary cholangitis (PBC), based on interactions with the FDA.
  • The trial consisted of a single ascending dose (SAD) part and a multiple ascending dose (MAD) part with dosing up to 1600mg/day.
  • Previously, doses of up to 800 mg/day were evaluated in a 24-week Phase 2 trial in PBC patients.

Positive Phase 1 results in high-dose setanaxib trial

Retrieved on: 
Monday, January 18, 2021

The Phase 1 study demonstrated that setanaxib is well tolerated at the doses tested, with no safety signal or dose-limiting toxicity being identified.

Key Points: 
  • The Phase 1 study demonstrated that setanaxib is well tolerated at the doses tested, with no safety signal or dose-limiting toxicity being identified.
  • The results provide an opportunity for the company to pursue a pivotal Phase 2/3 clinical trial in patients with primary biliary cholangitis (PBC), based on interactions with the FDA.
  • The trial consisted of a single ascending dose (SAD) part and a multiple ascending dose (MAD) part with dosing up to 1600mg/day.
  • Previously, doses of up to 800 mg/day were evaluated in a 24-week Phase 2 trial in PBC patients.

Translate Bio Announces Timing of Interim Results from mRNA Therapeutic Clinical Trial in Patients with Cystic Fibrosis; Data Expected in Early Q2 2021

Retrieved on: 
Thursday, January 7, 2021

The Company anticipates reporting interim clinical data from these cohorts early in the second quarter of 2021.

Key Points: 
  • The Company anticipates reporting interim clinical data from these cohorts early in the second quarter of 2021.
  • Translate Bio previously reported the first interim analysis data from the Phase 1/2 clinical trial which included 8, 16 and 24 mg single-ascending dose groups.
  • In July 2019, the Company announced interim results from the 8, 16 and 24 mg SAD groups of the Phase 1/2 clinical trial.
  • Translate Bios lead pulmonary candidate is being evaluated as an inhaled treatment for cystic fibrosis (CF) in a Phase 1/2 clinical trial.

Outlook on the 2020 Liver Fibrosis Industry - Clinical Trial Pipeline Highlights - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 8, 2020

The "Global Liver Fibrosis Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Liver Fibrosis Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides the most up-to-date information on key pipeline products in the global Liver Fibrosis market.
  • It covers emerging therapies for Liver Fibrosis in active clinical development stages including early and late-stage clinical trials.
  • The report provides Liver Fibrosis pipeline products by clinical trial stages including both early and late-stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Global Diabetic Nephropathy Market - 2020 Clinical Trial Pipeline Highlights - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 2, 2020

The "Global Diabetic Nephropathy Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Diabetic Nephropathy Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides the most up-to-date information on key pipeline products in the global Diabetic Nephropathy market.
  • It covers emerging therapies for Diabetic Nephropathy in active clinical development stages including early and late-stage clinical trials.
  • The report provides Diabetic Nephropathy pipeline products by clinical trial stages including both early and late-stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Genkyotex Reports Progress of Setanaxib Phase 2 Investigator Initiated Trials

Retrieved on: 
Tuesday, December 3, 2019

Philippe Wiesel, CMO of Genkyotex, said: We are very pleased to report positive developments in both the DKD and IPF clinical trials.

Key Points: 
  • Philippe Wiesel, CMO of Genkyotex, said: We are very pleased to report positive developments in both the DKD and IPF clinical trials.
  • Our recent results in PBC provided important dose response and safety information, which is being utilized to optimize these Phase II trials.
  • Setanaxib is also being evaluated in an investigator-initiated Phase II clinical trial in Type 1 Diabetes and Kidney Disease (DKD).
  • Genkyotex products are currently used for clinical trials only and are not otherwise available for distribution or sale.